Abstract
Cytochrome P450 2C9 (CYP2C9) is an important member of the cytochrome P450 enzyme superfamily with responsibility for metabolizing many important exogenous and endogenous compounds in many species of microorganisms, plants and animals. CYP2C9 is related to the oxidative of 16% of all therapeutics in current clinical use and has adverse drug effects, such as, enzyme induction and inhibition. In order to understand the metabolic mechanism of various drugs, two crystal structures of CYP2C9 have been studied, and their structural differences and structure-activity relationships with the drugs of Fluoxetine, Ibuprofen, Naproxen, Suprofen, and Mefenamic acid were investigated. By a series of docking studies and MD simulations, the binding pockets of CYP2C9 for the five drugs are explicitly defined that will be very useful for conducting mutagenesis studies, providing insights into the metabolic mechanism, which may be of relevance to the personalized drug.
Keywords: CYP2C9, cytochrome P-450, structure-activity relationship, metabolic mechanism
Medicinal Chemistry
Title: Binding of CYP2C9 with Diverse Drugs and its Implications for Metabolic Mechanism
Volume: 5 Issue: 3
Author(s): Jing-Fang Wang, Jing-Yi Yan, Dong-Qing Wei and Kuo-Chen Chou
Affiliation:
Keywords: CYP2C9, cytochrome P-450, structure-activity relationship, metabolic mechanism
Abstract: Cytochrome P450 2C9 (CYP2C9) is an important member of the cytochrome P450 enzyme superfamily with responsibility for metabolizing many important exogenous and endogenous compounds in many species of microorganisms, plants and animals. CYP2C9 is related to the oxidative of 16% of all therapeutics in current clinical use and has adverse drug effects, such as, enzyme induction and inhibition. In order to understand the metabolic mechanism of various drugs, two crystal structures of CYP2C9 have been studied, and their structural differences and structure-activity relationships with the drugs of Fluoxetine, Ibuprofen, Naproxen, Suprofen, and Mefenamic acid were investigated. By a series of docking studies and MD simulations, the binding pockets of CYP2C9 for the five drugs are explicitly defined that will be very useful for conducting mutagenesis studies, providing insights into the metabolic mechanism, which may be of relevance to the personalized drug.
Export Options
About this article
Cite this article as:
Wang Jing-Fang, Yan Jing-Yi, Wei Dong-Qing and Chou Kuo-Chen, Binding of CYP2C9 with Diverse Drugs and its Implications for Metabolic Mechanism, Medicinal Chemistry 2009; 5 (3) . https://dx.doi.org/10.2174/157340609788185954
DOI https://dx.doi.org/10.2174/157340609788185954 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does Eta Protein Differentiate Rheumatoid Arthritis from Psoriatic Arthritis?
Current Medicinal Chemistry Application of Baculovirus-Insect Cell Expression System for Human Therapy
Current Pharmaceutical Biotechnology Chest CT Features of Patients with COVID-19 Pneumonia Following Hospital Discharge
Current Medical Imaging Severity of COVID-19 in Pregnant Women: A Review on the Potential Role of Regulatory T Cells
Current Medicinal Chemistry The Structures and Bioactivities of Fatty Acid Synthase Inhibitors
Current Medicinal Chemistry Histamine H4 Receptor: A Novel Target for Inflammation Therapy
Mini-Reviews in Medicinal Chemistry Recent Advances in the Discovery of Novel Peptide Inhibitors Targeting 26S Proteasome
Anti-Cancer Agents in Medicinal Chemistry Protease Inhibitors in the Clinic
Medicinal Chemistry Computer-Aided Drug Design of Pyranopyrazoles and Related Compounds for Checkpoint Kinase-1
Letters in Drug Design & Discovery Design, Synthesis, and Biological Activity of a Novel Series of 2-Ureidonicotinamide Derivatives Against Influenza A Virus
Current Medicinal Chemistry Pharmacophore Models and Development of Spirocyclic Ligands for σ1 Receptors
Current Pharmaceutical Design A Review of Thyroid Dysfunction Due to COVID-19
Mini-Reviews in Medicinal Chemistry Green Solvent: Green Shadow on Chemical Synthesis
Current Organic Synthesis Multiscale Mapping of AIDS in U.S. Countries vs Anti-HIV Drugs Activity with Complex Networks and Information Indices
Current Bioinformatics Non Peptidic αvβ3 Antagonists: Recent Developments
Current Medicinal Chemistry An Overview on the Pharmacokinetics of Quantum Dots
Current Drug Metabolism Effect of Teleyoga Before COVID-19 and During Pandemic: A Narrative Review
Recent Advances in Anti-Infective Drug Discovery Novel Natural and Synthetic Ligands of the Endocannabinoid System
Current Medicinal Chemistry GABA System as a Target for New Drugs
Current Medicinal Chemistry G Protein β γ Subunits as Targets for Small Molecule Therapeutic Development
Combinatorial Chemistry & High Throughput Screening